Effect of enteric-coated mycophenolate sodium (EC-MPS) plus valsartan as part of intensified multi-factorial intervention compared to EC-MPS plus standard practice of care on development of transplant nephropathy in cadaver donor kidney recipients given basiliximab, cyclosporine microemulsion (CsA-ME) and short-term steroids: a 12-month, prospective, randomized, open-label multicentre study (MYTHOS).

Trial Profile

Effect of enteric-coated mycophenolate sodium (EC-MPS) plus valsartan as part of intensified multi-factorial intervention compared to EC-MPS plus standard practice of care on development of transplant nephropathy in cadaver donor kidney recipients given basiliximab, cyclosporine microemulsion (CsA-ME) and short-term steroids: a 12-month, prospective, randomized, open-label multicentre study (MYTHOS).

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2011

At a glance

  • Drugs Basiliximab; Ciclosporin; Corticosteroids; Mycophenolate sodium; Valsartan
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms MYTHOS
  • Sponsors Novartis
  • Most Recent Events

    • 28 Jan 2011 Actual end date (Jun 2005) added as reported by ClinicalTrials.gov.
    • 28 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top